GMAB vs ONC
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GMAB · Genmab$53.63 ▲ 1.69%
ONC · BeiGene$406.96 ▲ 5.09%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GMAB +84.5%
- ONC +23.6%
Head to head
| Metric | GMAB | ONC |
|---|---|---|
| Price | $53.63 | $406.96 |
| Change today | ▲ 1.69% | ▲ 5.09% |
| Market cap | $33.47B | $46.49B |
| Return, 3 months | +73.7% | +13.4% |
| Return, year to date | +74.1% | +34.0% |
| Return, 1 year | +87.1% | +27.2% |
| P/E (TTM) | 45.8 | 51.8 |
| P/B | 5.3 | 8.0 |
| P/E percentile vs own 5y | 84th | 79th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +16.1% | +29.6% |
| Net profit growth (YoY) | -14.7% | +151.3% |
| Gross margin | 92.7% | 88.9% |
| Operating margin | 30.6% | 15.1% |
| Net margin | 17.0% | 10.7% |
| Return on equity | 12.1% | 14.7% |
| Analyst target vs. price | +20.7% | +10.1% |
| Analyst buy share | 89% | 100% |
| RSI (14) | 71 | 68 |
| 30-day volatility | 86.7% | 38.2% |
| Max drawdown, 1 year | -32.5% | -31.0% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ONC is the largest of the group by market value.
- GMAB has returned the most over the past year.
- GMAB carries the lowest trailing P/E.
- ONC is growing revenue fastest.
- GMAB keeps the most profit per dollar of sales.
- ONC has been the calmest stock over the last 30 days.